<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nitrazepam (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nitrazepam (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nitrazepam (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="10915" href="/d/html/10915.html" rel="external">see "Nitrazepam (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52865472"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mogadon</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F3950304"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Benzodiazepine</li></ul></div>
<div class="block doa drugH1Div" id="F3950332"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Reduce dose or avoid use in patients receiving opioids. Avoid use in patients with a history of substance use, misuse of medications, or depression (Craske 2022).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61054428-193a-4786-a37f-55b82ea34457">Insomnia, sleep onset or sleep maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia, sleep onset or sleep maintenance (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Due to risk of next day impairment, dependence, and habituation, benzodiazepines should be reserved for patients in whom alternative, safer therapies for insomnia have failed (Neubauer 2021). When used, limit long-term use (&gt;4 weeks) to cases for which nonpharmacologic treatments are not available or not effective and benefits are felt to outweigh risks (ACP [Qaseem 2016]; ESRS [Riemann 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily at bedtime, as needed.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Reduce by 25% of the original dose every 1 to 2 weeks until lowest available dose is reached, then discontinue. Patients on long-term therapy or in whom discontinuation has previously failed may benefit from a slower taper in conjunction with cognitive behavioral therapy for insomnia (Bélanger 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991404"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988637"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F3950333"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Insomnia:</b> Elderly or debilitated patients: <b>Note: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>). <b>Oral:</b> Initial: 2.5 mg once daily, as needed, at bedtime; may increase dose to 5 mg at bedtime if tolerated (maximum dose: 5 mg/day).</p></div>
<div class="block dop drugH1Div" id="F3950331"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0a29f580-0de5-4c5a-9c84-1b7cf7e6ef81">Myoclonic seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myoclonic seizures:</b> Infants and Children ≤30 kg: Oral: Usual dosage: 0.3 to 1 mg/kg/day in 3 equally divided doses; if doses are not divided equally, administer larger dose at bedtime. <b>Note:</b> Therapy should be initiated below the usual dosage range and titrated carefully based on response. If inadequate response to usual dosage, may gradually increase dose further. Manufacturer labeling does not specify a maximum dosage.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131209"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51131210"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is contraindicated.</p></div>
<div class="block adr drugH1Div" id="F245352"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatological reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, diarrhea, dyspepsia, heartburn, nausea, sialorrhea (Jan 1971), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Granulocytopenia, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (depressed dreaming), abnormality in thinking, aggressive behavior, amnesia (including anterograde amnesia), apprehension, asthenia, ataxia (Jan 1971), behavioral changes (including disinhibition, inappropriate behavior), complex sleep-related disorder (including sleep driving), confusion, depersonalization, depression, disorientation, dizziness, drowsiness (Jan 1971), drug abuse, drug dependence (Clift 1972), emotional lability, falling, fatigue, hallucination, hangover effect (Charles 1987), headache, hypothermia (Impallomeni 1976), lethargy, nervousness, nightmares (Girwood 1973), paresthesia (MacLean 1973), sedated state, staggering, suicidal ideation, suicidal tendencies, withdrawal syndrome (including catatonia, delirium, muscle rigidity, rebound anxiety, rebound insomnia, tremor) (Adam 1976; Mackinnon 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, increased bronchial secretions (Jan 1971)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Paradoxical reaction (Nassr 1986)</p></div>
<div class="block coi drugH1Div" id="F245361"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to nitrazepam, benzodiazepines, or any component of the formulation; myasthenia gravis; severe respiratory insufficiency (eg, significant sleep apnea syndrome); severe hepatic insufficiency; use as hypnotic in children</p></div>
<div class="block war drugH1Div" id="F245350"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/anaphylactoid reactions: Have been reported with use (rare); patients who develop angioedema should not be rechallenged with nitrazepam.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999). May also rarely induce transient global amnesia or traveler's amnesia (if taken to induce sleep while traveling); caution patients to ensure they have uninterrupted sleep of 7 to 8 hours after ingestion of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Aspiration pneumonia: Bronchial hypersecretion and excessive salivation/drooling leading to aspiration pneumonia in young and elderly patients may occur rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines; risk may be increased in adolescent/pediatric patients, geriatric patients, or patients with a history of alcohol use disorder or psychiatric/personality disorders (Mancuso 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Rebound insomnia: Following withdrawal of therapy, transient insomnia may recur accompanied by other reactions including restlessness, anxiety, and mood changes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (contraindicated in severe hepatic impairment).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression. Use is contraindicated in severe respiratory insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep apnea: Benzodiazepines can suppress respiratory drive in patients with obstructive sleep apnea; use caution when prescribing for insomnia in this population (Webster 2020). Nitrazepam is contraindicated in cases of clinically significant sleep apnea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults. Older adult patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Associated with sudden death in children &lt;5 years of age being treated for seizure disorders (Murphy 1987; Rintahaka 1999). Use should be restricted to children unresponsive to other antiseizure agents. Higher doses may cause excessive drowsiness and bronchial hypersecretion in infants and young children; evaluate infants prior to initiation of therapy to determine if upper airway is clear.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypnotic: Appropriate use: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate psychiatric and/or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation. Reassess patient for appropriateness of continued use after 2 to 3 weeks of consecutive treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rebound insomnia: Following withdrawal of therapy, transient insomnia may recur accompanied by other reactions, including restlessness, anxiety, and mood changes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Nitrazepam is a long half-life benzodiazepine; duration of action after a single dose is determined by redistribution rather than metabolism (Brunton 2011). Tolerance develops to the hypnotic and antiseizure effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: A longer sleep-onset latency and increased awakenings during sleep may occur for 1 to 2 days following the discontinuation of GABA-mediated (GABAergic) medications. A more severe withdrawal syndrome may rarely occur following abrupt discontinuation or large decreases in dose after sustained use (&gt;10 days), and is characterized by new-onset agitation, ataxia, depersonalization, dizziness, dysphoria, fatigue, headache, hypersensitivity to stimuli, irritability, muscle cramps or pain, nausea, sweating, twitching, vomiting, and weakness. This withdrawal syndrome generally resolves within weeks or upon reinitiation of the GABAergic medication. Intermittent dosing may reduce the risk of withdrawal symptoms (BAP [Wilson 2019]). Use caution when reducing dose or withdrawing therapy; avoid abrupt discontinuation; decrease slowly and monitor for withdrawal symptoms.</p></div>
<div class="block prod-avail drugH1Div" id="F11234093"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040703"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block dinfoc drugH1Div" id="F52865473"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mogadon: 5 mg, 10 mg</p></div>
<div class="block csi drugH1Div" id="F3950277"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">CDSA IV</p></div>
<div class="block adm drugH1Div" id="F3950334"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Tablets may be swallowed whole, crushed, or dissolved in liquid. For insomnia, administer at bedtime. For myoclonic seizures, administer in 3 equally divided doses, or if doses are not divided equally, give larger dose at bedtime.</p></div>
<div class="block admp drugH1Div" id="F52614106"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: <i>Myoclonic seizures: </i>Tablets may be swallowed whole, crushed, or dissolved in liquid. Administer in 3 equally divided doses, or if doses are not divided equally, give larger dose at bedtime.</p></div>
<div class="block use drugH1Div" id="F245358"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Insomnia, sleep onset or sleep maintenance:</b> Short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Limitations of use</i>: Restrict use to insomnia that impairs normal daytime functioning. Treatment should typically not exceed 7 to 10 consecutive days. Reevaluation of the patient is required if treatment continues for &gt;2 to 3 consecutive weeks. Prescriptions should be written for short-term use (7 to 10 days) and limited to ≤1 month supply.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b> Management of myoclonic seizures in children.</p></div>
<div class="block mst drugH1Div" id="F46122857"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Benzodiazepines (nitrazepam) are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299765"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F245353"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: May enhance the hepatotoxic effect of Nitrazepam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Nitrazepam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F3950305"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nitrazepam crosses the placenta (Kangas 1977).</p>
<p style="text-indent:0em;margin-top:2em;">In-utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors) (Iqbal 2002). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to benzodiazepines in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal (Iqbal 2002).</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for insomnia in pregnant patients should be individualized. Untreated insomnia may lead to adverse pregnancy outcomes. Although recommendations vary, nonpharmacologic therapy is preferred as an initial treatment of insomnia during pregnancy (BAP [McAllister-Williams 2017]; BAP [Wilson 2019]; Palagini 2022).</p></div>
<div class="block brc drugH1Div" id="F3950308"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam is present in breast milk (Kangas 1981; Matheson 1990).</p>
<p style="text-indent:-2em;margin-left:2em;">Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines, including nitrazepam (Iqbal 2002; Speight 1977).</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding during benzodiazepine therapy is not recommended due to the potential for drowsiness in the breastfed infant (Larsen 2015). Breastfeeding is not recommended by the manufacturer. Infants exposed to nitrazepam via breast milk should be monitored for adverse events, including irritability and sedation.</p></div>
<div class="block mop drugH1Div" id="F3950336"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory, cardiovascular, and mental status</p></div>
<div class="block rer drugH1Div" id="F245357"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Steady state levels after 4 days: 40 ng/mL</p></div>
<div class="block pha drugH1Div" id="F245349"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Intermediate-acting benzodiazepine (based on half-life) (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>
<div class="block phk drugH1Div" id="F245360"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 20 to 50 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Classified as an intermediate-acting benzodiazepine; classification based on benzodiazepines with half-life of 12 to 40 hours (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 2.4 L/kg (range: 1.6 to 3.2 L/kg), Elderly: 4.8 L/kg (range: 3.1 to 6.5 L/kg); also distributes into CSF, saliva (Kangas 1979).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 87%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic: Nitroreduction, acetylation; no active metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 30 hours (range: 18 to 57 hours), Elderly/ill patients: 40 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (65% to 71%, ~1% as unchanged drug); feces (14% to 20%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869334"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Somnite</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alodorm | Mogadon</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Amoctin | Epam | Eunoctin | Noctin | Relactin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Nitrazepam teva generics belgium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Berlidorm | Radedorm</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nitrapan | Nitrazepol | Sonebon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dormalon | Dormalon nitrazepam | Imeson | Mogadon | Nitrazepam al | Novanox</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hipnotab | Quill</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Somnil</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Berlidorm | Dima-10 | Eatan n | Eunoctin | Nitrazepam accord | Nitrazepam-alpharma | Nomefren | Radedorm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nitrazepan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Apodorm | Insomin | Mogadon | Nitrazepam accord | Pacisyn | Somitran</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Nitrados | Nitrazepam almus | Nitrazepam arrow | Nitrazepam berk | Nitrazepam dc | Nitrazepam kent | Nitreeze | Noctesed | Remnos | Somnased | Somnite | Unisomnia</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dima | Mogadon | Nipa</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cerson</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Eunoctin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dumolid | Mogadon | Somnil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Somnite</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Numbon</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Baronite | Calmtra | Dormin | Halonite | Hypnoril | Manonit | Nicare | Nidra | Nigap | Nipam | Nira | Nitavan | Nitcalm | Nite | Nithra | Nitpro | Nitraplan | Nitravet | Nitrosun | Nitrosym | Niz | Stressban</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Benzalin | Calsmin | Chiorazepam | Cysvon | Hirusukamin | Nelbon | Nelmat | Nelurolen | Nemnamine | Neuchlonic | Nitrazepam amel | Nitrazepam bmj | Nitrazepam nichiiko | Nitrazepam okura | Nitrazepam teva | Nitrazepam towa | Nitrazepam zensei</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Berlidorm | Eunoctin | Imeson | Nitrazepam bp | Radedorm</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Berlidorm | Eunoctin | Imeson | Nitrazepam accord | Radedorm | Sleep</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Nitramin | Nitrapam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Nitrazepam A | Nitrazepam Actavis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apodorm | Mogadon | Nitrazepam accord</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Insoma | Nitrados</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Nitpam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nomefren | Radedorm</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Berlidorm | Eunoctin | Nitrosan | Nozepam | Radedorm</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Apodorm | Dumolid | Mogadon | Nitrazepam recip</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dima | Nitrados</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cerson</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alodorm | Eunoctin | Mogadon | Nitrados</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">An-sleeper | Answet | Hirusukamin | Limin | Mogadon | Mudamin | Nitraze | Nitromin | Osmin | Sleep | Sleepin | Slomin | Susui</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Berlidorm | Eunoctin | Nitrosun | Radedorm</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mogadon</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mogadon | Onirema</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Arem | Mogadon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-179657">
<a name="179657"></a>Adam K, Adamson L, Brezinová V, Hunter WM. Nitrazepam: lastingly effective but trouble on withdrawal. <i>Br Med J</i>. 1976;1(6025):1558-1560. doi:10.1136/bmj.1.6025.1558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/179657/pubmed" id="179657" target="_blank">179657</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bélanger L, Belleville G, Morin C. Management of hypnotic discontinuation in chronic insomnia. <i>Sleep Med Clin</i>. 2009;4(4):583-592. doi:10.1016/j.jsmc.2009.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/20607118/pubmed" id="20607118" target="_blank">20607118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp Psychiatry.</i> 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. McGraw-Hill Medical; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3620293">
<a name="3620293"></a>Charles RB, Kirkham AJ, Guyatt AR, Parker SP. Psychomotor, pulmonary and exercise responses to sleep medication. <i>Br J Clin Pharmacol</i>. 1987;24(2):191-197. doi:10.1111/j.1365-2125.1987.tb03161.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/3620293/pubmed" id="3620293" target="_blank">3620293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention- deficit/hyperactivity disorders. <i>JAMA Netw Open.</i> 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5071698">
<a name="5071698"></a>Clift AD. Factors leading to dependence on hypnotic drugs. <i>Br Med J</i>. 1972;3(5827):614-617. doi:10.1136/bmj.3.5827.614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/5071698/pubmed" id="5071698" target="_blank">5071698</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18998740">
<a name="18998740"></a>Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. <i>CNS Drugs.</i> 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/18998740/pubmed" id="18998740" target="_blank">18998740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. <i>Gen Hosp Psychiatry.</i> 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4685632">
<a name="4685632"></a>Girwood RH. Nitrazepam nightmares. <i>Br Med J</i>. 1973;1(5849):353. doi:10.1136/bmj.1.5849.353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/4685632/pubmed" id="4685632" target="_blank">4685632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta- analysis. <i>J Clin Psychiatry</i>. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1247796">
<a name="1247796"></a>Impallomeni M, Ezzat R. Letter: Hypothermia associated with nitrazepam administration. <i>Br Med J</i>. 1976;1(6003):223-224. doi:10.1136/bmj.1.6003.223-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/1247796/pubmed" id="1247796" target="_blank">1247796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T, et al. Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant. <i>Psychiatr Serv</i>. 2002;53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5550546">
<a name="5550546"></a>Jan JE, Riegl JA, Crichton JU, Dunn HG. Nitrazepam in the treatment of epilepsy in childhood. <i>Can Med Assoc J</i>. 1971;104(7):571-575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/5550546/pubmed" id="5550546" target="_blank">5550546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. <i>Eur Neuropsychopharmacol</i>. 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-474154">
<a name="474154"></a>Kangas L, Allonen H, Lammintausta R, et al. Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose. <i>Acta Pharmacol Toxicol (Copenh)</i>. 1979;45(1):20-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/474154/pubmed" id="474154" target="_blank">474154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7037262">
<a name="7037262"></a>Kangas L, Breimer DD. Clinical pharmacokinetics of nitrazepam. <i>Clin Pharmacokinet</i>. 1981;6(5):346-366. doi:10.2165/00003088-198106050-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/7037262/pubmed" id="7037262" target="_blank">7037262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-598407">
<a name="598407"></a>Kangas L, Kanto J, Erkkola R. Transfer of nitrazepam across the human placenta. <i>Eur J Clin Pharmacol.</i> 1977;12(5):355-357. doi:10.1007/BF00562451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/598407/pubmed" id="598407" target="_blank">598407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6133446">
<a name="6133446"></a>MacKinnon GL, Parker WA. Benzodiazepine withdrawal syndrome: a literature review and evaluation. <i>Am J Drug Alcohol Abuse</i>. 1982;9(1):19-33. doi:10.3109/00952998209002608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/6133446/pubmed" id="6133446" target="_blank">6133446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4689857">
<a name="4689857"></a>MacLean H. Nitrazepam: another interesting syndrome. <i>Br Med J</i>. 1973;1(5851):488. doi:10.1136/bmj.1.5851.488-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/4689857/pubmed" id="4689857" target="_blank">4689857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2288825">
<a name="2288825"></a>Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. <i>Br J Clin Pharmacol.</i> 1990;30(6):787-793. doi:10.1111/j.1365-2125.1990.tb05443.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/2288825/pubmed" id="2288825" target="_blank">2288825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al; endorsed by the British Association for Psychopharmacology. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>J Psychopharmacol</i>. 2017;31(5):519-552. doi:10.1177/0269881117699361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mogadon (nitrazepam) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3598778">
<a name="3598778"></a>Murphy JV, Sawasky F, Marquardt KM, et al. Deaths in Young Children Receiving Nitrazepam. <i>J Pediatr</i>. 1987;111(1):145-147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/3598778/pubmed" id="3598778" target="_blank">3598778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3700699">
<a name="3700699"></a>Nassr DG. Paradoxical response to nitrazepam in a patient with hypersomnia secondary to nocturnal myoclonus. <i>J Clin Psychopharmacol</i>. 1986;6(2):121-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/3700699/pubmed" id="3700699" target="_blank">3700699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology.<i> Can J Clin Pharmacol.</i> 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Neubauer DN. Pharmacotherapy for insomnia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med</i>. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35419652">
<a name="35419652"></a>Palagini L, Bramante A, Baglioni C, et al. Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force "Sleep and Women," the Italian Marcè Society and international experts task force for perinatal mental health. <i>Arch Womens Ment Health</i>. 2022;25(3):561-575. doi:10.1007/s00737-022-01226-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/35419652/pubmed" id="35419652" target="_blank">35419652</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med</i>. 2016;165(2):125-133. doi:10.7326/M15-2175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/27136449/pubmed" id="27136449" target="_blank">27136449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol.</i> 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. <i>J Sleep Res</i>. 2017;26(6):675-700. doi:10.1111/jsr.12594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/28875581/pubmed" id="28875581" target="_blank">28875581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10219277">
<a name="10219277"></a>Rintahaka PJ, Nakagawa JA, Shewmon DA, et al. Incidence of Death in Patients with Intractable Epilepsy During Nitrazepam Treatment. <i>Epilepsia</i>. 1999;40(4):492-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/10219277/pubmed" id="10219277" target="_blank">10219277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. <i>Int J Geriatr Psychiatry.</i> 2018;33(4):583-590. doi:10.1002/gps.4821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-72227">
<a name="72227"></a>Speight AN. Floppy-infant syndrome and maternal diazepam and/or nitrazepam. <i>Lancet</i>. 1977;2(8043):878. doi:10.1016/s0140-6736(77)90817-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/72227/pubmed" id="72227" target="_blank">72227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. <i>JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. <i>Depress Anxiety.</i> 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.1">
<a name="VADoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of chronic insomnia disorder and obstructive sleep apnea. <a href="https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/CD/insomnia/VADoDSleepCPGFinal508.pdf</a>. Published October 2019. Accessed April 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. <i>Neurosci Biobehav Rev.</i> 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33021707">
<a name="33021707"></a>Webster LR, Karan S. The physiology and maintenance of respiration: a narrative review. <i>Pain Ther</i>. 2020;9(2):467-486. doi:10.1007/s40122-020-00203-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/33021707/pubmed" id="33021707" target="_blank">33021707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, et al. Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(11):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31271339">
<a name="31271339"></a>Wilson S, Anderson K, Baldwin D, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update.<i> J Psychopharmacol</i>. 2019;33(8):923-947. doi:10.1177/0269881119855343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nitrazepam-united-states-not-available-drug-information/abstract-text/31271339/pubmed" id="31271339" target="_blank">31271339</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10165 Version 240.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
